ArticleWorld journal of psychiatry2015
Conceptualization and treatment of negative symptoms in schizophrenia.
Article in World journal of psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06127004 (Metacognitive Training for Negative Symptoms), which is not on this map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Metacognitive Training for Negative Symptoms (MCT Minus)
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Quality of life among people living with mental illness and predictors in Africa: a systematic review and meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Pooled it
- Clarifying the overlap between motivation and negative symptom measures in schizophrenia research: A meta-analysis.Schizophrenia research · 2019Pooled it
- Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: a randomized, double-blind, placebo-controlled trial.The international journal of neuropsychopharmacology · 2024Trial
- The NLRP3 inflammasome: pathophysiology and therapeutic implications for schizophrenia and neuropsychiatric disorders.Molecular psychiatry · 2026Review
- Social and Clinical Factors Associated With Antipsychotic Medication Discontinuation in Patients With Schizophrenia.International journal of methods in psychiatric research · 2026Article
- More Severe Brain Network Hierarchy Disorganization in Treatment-Naive Deficit Compared to Non-deficit Schizophrenia and Underlying Neurotransmitter Associations.Schizophrenia bulletin · 2026Article
- Passive sensing of anhedonia and amotivation in a transdiagnostic sample.Journal of psychopathology and clinical science · 2025Article
- Neuro- and social-cognition in schizotypal personality disorder and schizophrenia: A spectrum of severity.Psychiatry research · 2025Article
- Probabalistic reinforcement learning impairments predict negative symptom severity and risk for conversion in youth at clinical high-risk for psychosis.Psychological medicine · 2025Article
- Social functioning and frontal alpha asymmetry in schizophrenia.Journal of psychiatric research · 2025Article
- How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.Frontiers in psychiatry · 2025Article
- The relationship between sarcopenic obesity and cognitive functionality among inpatients with stable schizophrenia.PloS one · 2025Article
- Influence of Polymorphisms in Gene SATB2 on Antipsychotics Response in Chinese Han Population.Neuropsychiatric disease and treatment · 2025Article
- On the improvement of schizophrenia detection with optical coherence tomography data using deep neural networks and aggregation functions.Scientific reports · 2024Article
- A Transdiagnostic Study of Effort-Cost Decision-Making in Psychotic and Mood Disorders.Schizophrenia bulletin · 2024Article
- Impact of cognitive performance and negative symptoms on psychosocial functioning in Czech schizophrenia patients.Schizophrenia (Heidelberg, Germany) · 2023Article
- Deficit Symptomatology of Schizophrenia Is Associated with Attenuated Taste Identification: Findings from a Cross-Sectional Study.Brain sciences · 2022Article
- Article
- Evaluating the item-level factor structure of anhedonia.Journal of affective disorders · 2022Article
- Dynamic Interplay Between Insight and Persistent Negative Symptoms in First Episode of Psychosis: A Longitudinal Study.Schizophrenia bulletin · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Negative symptoms of schizophrenia including social withdrawal, diminished affective response, lack of interest, poor social drive, and decreased sense of purpose or goal directed activity predict poor functional outcomes for patients with schizophrenia. They may develop and be maintained as a result of structural and functional brain abnormalities, particularly associated with dopamine reward pathways and by environmental and psychosocial factors such as self-defeating cognitions and the relief from overstimulation that accompanies withdrawal from social and role functioning. Negative symptoms are more difficult to treat than the positive symptoms of schizophrenia and represent an unmet therapeutic need for large numbers of patients with schizophrenia. While antipsychotic medications to treat the symptoms of schizophrenia have been around for decades, they have done little to address the significant functional impairments in the disorder that are associated with negative symptoms. Negative symptoms and the resulting loss in productivity are responsible for much of the world-wide personal and economic burden of schizophrenia. Pharmacologic treatments may be somewhat successful in treating secondary causes of negative symptoms, such as antipsychotic side effects and depression. However, in the United States there are no currently approved treatments for severe and persistent negative symptoms (PNS) that are not responsive to treatments for secondary causes. Pharmacotherapy and psychosocial treatments are currently being developed and tested with severe and PNS as their primary targets. Academia, clinicians, the pharmaceutical industry, research funders, payers and regulators will need to work together to pursue novel treatments to address this major public health issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.